Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Hurler Syndrome
100%
Reduced Intensity
100%
Preparative Regimen
100%
Hematopoietic Cell Transplantation
40%
Donor chimerism
40%
Graft-versus-host Disease (GvHD)
20%
Deleterious Effects
20%
Donor Graft
20%
Grafting from
20%
Engraftment
20%
Severe Acute
20%
Neurologic
20%
Alemtuzumab
20%
Transplant Outcomes
20%
Two-center
20%
Donor Engraftment
20%
Unrelated Donor
20%
Fludarabine
20%
Melphalan
20%
Sibling Donor
20%
Delayed Losses
20%
Medicine and Dentistry
Cell Transplantation
100%
Hurler Syndrome
100%
Hematopoietic Cell
100%
Graft Versus Host Reaction
60%
Transplantation
40%
Chimera
40%
Engraftment
40%
Immunosuppressive Drug
20%
Alemtuzumab
20%
Fludarabine
20%
Melphalan
20%
Immunology and Microbiology
Hematopoietic Cell
100%
Cell Transplantation
100%
Graft-Versus-Host Disease
75%
Engraftment
50%
Chimera
50%
Immunosuppressive Drug
25%
Alemtuzumab
25%
Biochemistry, Genetics and Molecular Biology
Hurler Syndrome
100%
Cell Transplantation
100%
Hematopoietic Cell
100%
Chimera
40%
Melphalan
20%
Alemtuzumab
20%
Fludarabine
20%
Pharmacology, Toxicology and Pharmaceutical Science
Hurler Syndrome
100%
Graft Versus Host Reaction
60%
Melphalan
20%
Immunosuppressive Agent
20%
Syndrome
20%
Alemtuzumab
20%
Fludarabine
20%